iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
iCAD (NASDAQ: ICAD) and RamSoft have announced a strategic commercial preferred distributor and integration partnership across the US and Canada. The collaboration will integrate iCAD's ProFound AI® Breast Health Suite into RamSoft's cloud-based RIS/PACS platform, serving over 750 sites worldwide.
The partnership aims to enhance workflow efficiency and diagnostic confidence in breast cancer detection. Mammolink will be the first organization to implement the integrated solution. The ProFound AI technology addresses the challenge of 20-40% of breast cancers remaining undetected by traditional screening mammography.
The integration will be available through RamSoft's PowerServer platform, which is FDA 510(k) cleared and IHE mammo profile compliant. The system features customizable layouts, MG CAD Markers support, and digital breast tomosynthesis (DBT) capabilities, streamlining workflow and improving diagnostic efficiency.
iCAD (NASDAQ: ICAD) e RamSoft hanno annunciato una partnership strategica come distributore preferito e per l'integrazione negli Stati Uniti e in Canada. La collaborazione integrerà il ProFound AI® Breast Health Suite di iCAD nella piattaforma RIS/PACS basata su cloud di RamSoft, servendo oltre 750 sedi in tutto il mondo.
La partnership mira a migliorare l'efficienza del flusso di lavoro e la fiducia diagnostica nella rilevazione del cancro al seno. Mammolink sarà la prima organizzazione a implementare la soluzione integrata. La tecnologia ProFound AI affronta la sfida del 20-40% dei tumori al seno che rimangono non rilevati dalla mammografia tradizionale.
L'integrazione sarà disponibile attraverso la piattaforma PowerServer di RamSoft, che è approvata dalla FDA 510(k) e conforme al profilo IHE mammo. Il sistema presenta layout personalizzabili, supporto per i marcatori MG CAD e capacità di tomosintesi digitale del seno (DBT), semplificando il flusso di lavoro e migliorando l'efficienza diagnostica.
iCAD (NASDAQ: ICAD) y RamSoft han anunciado una asociación estratégica como distribuidor preferido e integración en EE. UU. y Canadá. La colaboración integrará el ProFound AI® Breast Health Suite de iCAD en la plataforma RIS/PACS basada en la nube de RamSoft, sirviendo a más de 750 sitios en todo el mundo.
La asociación tiene como objetivo mejorar la eficiencia del flujo de trabajo y la confianza diagnóstica en la detección del cáncer de mama. Mammolink será la primera organización en implementar la solución integrada. La tecnología ProFound AI aborda el desafío del 20-40% de los cánceres de mama que permanecen no detectados por la mamografía de detección tradicional.
La integración estará disponible a través de la plataforma PowerServer de RamSoft, que cuenta con la aprobación de la FDA 510(k) y es compatible con el perfil mamográfico IHE. El sistema presenta diseños personalizables, soporte para marcadores MG CAD y capacidades de tomosíntesis digital de mama (DBT), optimizando el flujo de trabajo y mejorando la eficiencia diagnóstica.
iCAD (NASDAQ: ICAD)와 RamSoft는 미국과 캐나다 전역에서 전략적 상업 파트너십 및 통합 파트너십을 발표했습니다. 이 협력은 iCAD의 ProFound AI® Breast Health Suite를 RamSoft의 클라우드 기반 RIS/PACS 플랫폼에 통합하여 전 세계 750개 이상의 사이트에 서비스를 제공합니다.
이 파트너십의 목표는 유방암 검출에서 작업 효율성과 진단 신뢰성을 향상시키는 것입니다. Mammolink는 통합 솔루션을 구현하는 첫 번째 조직이 될 것입니다. ProFound AI 기술은 전통적인 스크리닝 유방촬영술로 발견되지 않는 20-40%의 유방암 문제를 해결합니다.
이 통합은 FDA 510(k) 승인을 받은 RamSoft의 PowerServer 플랫폼을 통해 제공되며, IHE 유방 프로파일과 호환됩니다. 이 시스템은 사용자 정의 가능한 레이아웃, MG CAD 마커 지원 및 디지털 유방 톰신세시스(DBT) 기능을 갖추고 있어 작업 흐름을 간소화하고 진단 효율성을 향상시킵니다.
iCAD (NASDAQ: ICAD) et RamSoft ont annoncé un partenariat stratégique en tant que distributeur préféré et partenaire d'intégration aux États-Unis et au Canada. La collaboration intégrera le ProFound AI® Breast Health Suite d'iCAD dans la plateforme RIS/PACS basée sur le cloud de RamSoft, servant plus de 750 sites dans le monde entier.
Ce partenariat vise à améliorer l'efficacité des flux de travail et la confiance diagnostique dans la détection du cancer du sein. Mammolink sera la première organisation à mettre en œuvre la solution intégrée. La technologie ProFound AI répond au défi des 20-40 % des cancers du sein qui restent non détectés par la mammographie de dépistage traditionnelle.
L'intégration sera disponible via la plateforme PowerServer de RamSoft, qui est approuvée par la FDA 510(k) et conforme au profil mammo IHE. Le système propose des mises en page personnalisables, un support pour les marqueurs MG CAD et des capacités de tomosynthèse numérique du sein (DBT), simplifiant le flux de travail et améliorant l'efficacité diagnostique.
iCAD (NASDAQ: ICAD) und RamSoft haben eine strategische Partnerschaft als bevorzugter Distributor und Integrationspartner in den USA und Kanada angekündigt. Die Zusammenarbeit wird iCADs ProFound AI® Breast Health Suite in die cloudbasierte RIS/PACS-Plattform von RamSoft integrieren, die über 750 Standorte weltweit bedient.
Das Ziel der Partnerschaft ist es, die Effizienz der Arbeitsabläufe und das diagnostische Vertrauen bei der Erkennung von Brustkrebs zu verbessern. Mammolink wird die erste Organisation sein, die die integrierte Lösung implementiert. Die ProFound AI-Technologie begegnet der Herausforderung, dass 20-40% der Brustkrebserkrankungen von herkömmlichen Screening-Mammographien unentdeckt bleiben.
Die Integration wird über die PowerServer-Plattform von RamSoft verfügbar sein, die von der FDA 510(k) genehmigt und IHE-Mammo-Profil-konform ist. Das System bietet anpassbare Layouts, Unterstützung für MG CAD-Markierungen und digitale Brusttomosynthese (DBT)-Funktionen, die den Arbeitsablauf optimieren und die diagnostische Effizienz verbessern.
- Strategic partnership expands access to 750+ healthcare sites
- Integration addresses 20-40% missed cancer detection rate
- FDA 510(k) cleared and IHE mammo compliant platform
- None.
Insights
This strategic partnership between iCAD and RamSoft represents a significant distribution channel expansion for iCAD's ProFound AI technology. With access to RamSoft's 750+ sites and thousands of providers, iCAD gains immediate entry into established clinical workflows without requiring site-by-site direct sales efforts—dramatically accelerating potential market penetration.
What makes this partnership particularly compelling is the integration approach. Rather than offering a standalone solution requiring separate implementation, ProFound AI will be embedded directly within RamSoft's PowerServer platform—the system radiologists already use daily. This integration strategy eliminates a major adoption barrier in healthcare technology: workflow disruption.
The partnership addresses a genuine clinical need highlighted by the
For RamSoft, adding advanced AI capabilities enhances their platform's value proposition in the competitive radiology software market, potentially improving customer retention and attracting new facilities seeking comprehensive solutions.
Mammolink's early adoption provides an important initial reference customer to demonstrate real-world implementation. The absence of financial terms prevents assessment of immediate revenue impact, but the strategic value of expanded distribution channels is clear. In the fragmented healthcare AI market, embedding technology into established platforms represents a savvy growth strategy.
This integration addresses a critical workflow challenge in breast imaging departments. Radiologists already face increasing study volumes and complexity, particularly with digital breast tomosynthesis generating hundreds of images per exam. The seamless integration of ProFound AI directly into the PowerServer platform eliminates the need to switch between systems or manually transfer findings—a significant efficiency advantage.
The clinical relevance cannot be overstated. With
Mammolink's adoption is notable as they specifically focus on improving accessibility to high-quality breast screening. The PowerServer integration enables customized layouts and unified worklists that maintain radiologists' preferred reading patterns while incorporating AI insights.
The technical specifications mentioned in the article are meaningful: FDA 510(k) clearance and IHE mammo profile compliance ensure regulatory standards are met, while DBT support addresses the growing adoption of 3D mammography technology. The viewer's support for CAD markers facilitates clearer communication of AI findings within existing workflows.
For radiologists, the primary value proposition is two-fold: potential improvement in diagnostic accuracy while simultaneously enhancing reading efficiency. This dual benefit addresses both quality and productivity concerns—a rare combination in healthcare technology where improvements in one dimension often come at the expense of the other.
NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft’s solutions, this collaboration brings iCAD’s ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use.
"iCAD’s partnership with RamSoft marks an important step in expanding access to AI-powered breast health solutions across North America," said Dana Brown, President and CEO of iCAD, Inc. "By integrating the ProFound Breast Health Suite into RamSoft’s leading RIS/PACS platform, we are equipping radiologists with the tools they need to enhance early detection and improve patient outcomes."
"RamSoft is committed to delivering innovative solutions that streamline radiology workflows and improve diagnostic accuracy," said Vijay Ramanathan, CEO and Co-Founder of RamSoft. "Our collaboration with iCAD allows us to provide an advanced AI-powered mammography solution that enhances efficiency and enables better patient care. The first organization that will jointly be incorporating ProFound AI Breast Health Suite via the RamSoft PowerServer platform is Mammolink."
"At Mammolink, our mission is to make high-quality breast cancer screening more accessible," said Dr. Ryan Polselli, Radiologist and Founder of Mammolink, a leading provider of 3D mammography and diagnostic ultrasound imaging services. "Integrating ProFound AI into our workflow via RamSoft’s PowerServer technology will allow us to deliver faster and more accurate results to the women who rely on us for timely, life-saving screenings."
With 20
iCAD’s ProFound AI Breast Health Suite will be integrated into the PowerServer cloud-based RIS/PACS platform designed to provide unmatched functionality, flexibility, and data management—even in the most demanding imaging environments. PowerServer is an advanced solution that is FDA 510(k) cleared and IHE mammo profile compliant, ensuring regulatory compliance and high standards of quality. It features customizable layouts, allowing radiologists to seamlessly navigate viewing steps for enhanced efficiency. Additionally, the viewer supports MG CAD Markers, aiding in precise interpretation, and includes digital breast tomosynthesis (DBT) support, enabling advanced imaging analysis. By unifying access to all related breast imaging studies within a single worklist, the PowerServer platform streamlines workflow, reduces redundant tasks, and improves overall diagnostic efficiency.
iCAD and RamSoft will be attending HIMSS 2025, from Monday, March 3-6, 2025 in the Venetian Convention & Expo Center, Las Vegas, NV. RamSoft will demonstrate its full line of cloud-based RIS/PACS software solutions including its newest AI-driven radiological solutions and its new patient portal, Blume, in booth #5039.
About RamSoft®
RamSoft is a global provider of innovative cloud-based radiology software solutions for imaging centers, radiology departments, and teleradiology providers. PowerServer™, utilized by over 750 sites and thousands of customers worldwide, offers a flexible, scalable design enabling imaging operations of all sizes to leverage comprehensive cloud-based RIS (Radiology Information System)/PACS (Picture Archiving and Communication System) capabilities. RamSoft’s latest offering, OmegaAI®, is a cloud-native AI-driven platform delivering rapid, secure, and robust RIS and PACS capabilities that are completely zero footprint, powered by Microsoft Azure. Additionally, Blume™ - Patient Portal allows patients to access, store and share their diagnostic imaging studies with referring physicians, family members and for personal record.
About Mammolink
MammoLink® is improving breast cancer screening by changing the relationship between doctors, radiologists, and patients to make mammograms more accessible. Operating 5 state-of-the-art mobile mammography buses, Mammolink provides accessible 3D mammography to women across Florida with guaranteed results provided within 24 hours. For more information, please visit www.MammoLink.com.
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven deep learning solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., USA, iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
iCAD Media Inquiries:
pr@icadmed.com
iCAD Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
RamSoft Inquiries:
Rob Sandler
Chief Marketing Officer
+1 647-361-4516
rob.sandler@ramsoft.com
FAQ
What is the significance of iCAD's partnership with RamSoft for mammography solutions?
How does ProFound AI technology improve breast cancer detection rates?
Which features are included in RamSoft's PowerServer platform for ICAD integration?
Who is the first organization implementing the iCAD-RamSoft integrated solution?
